At ESMO 2026, Sun Pharma to Present Long-Term Follow-up Data on UNLOXCYT® (cosibelimab-ipdl) from One of the Largest Prospective Studies in Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)

我校承办中国生物化学与分子生物学会2026年全国学术大会

Coreline Soft Receives U.S. FDA 510(k) Clearance for AVIEW Aorta Metrics, Expanding Its Chest CT AI Portfolio in the U.S.

2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS

Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026